Ronnie Tung‐ping Poon

Ronnie Tung‐ping Poon's AcademicInfluence.com Rankings

Philosophy

#7573

World Rank

#10807

Historical Rank

Logic

#4623

World Rank

#5939

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Why Is Ronnie Tung‐ping Poon Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Ronnie Tung‐ping Poon's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma (2002) (2397)
Significance of CD90+ cancer stem cells in human liver cancer. (2008) (1173)
Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma (2010) (1013)
Long-Term Survival and Pattern of Recurrence After Resection of Small Hepatocellular Carcinoma in Patients With Preserved Liver Function: Implications for a Strategy of Salvage Transplantation (2002) (813)
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. (2015) (697)
Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma (2000) (692)
Improving Perioperative Outcome Expands the Role of Hepatectomy in Management of Benign and Malignant Hepatobiliary Diseases: Analysis of 1222 Consecutive Patients From a Prospective Database (2004) (667)
Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. (2013) (649)
Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. (2015) (639)
Clinical implications of circulating angiogenic factors in cancer patients. (2001) (600)
Improving Survival Results After Resection of Hepatocellular Carcinoma: A Prospective Study of 377 Patients Over 10 Years (2001) (580)
Intrahepatic recurrence after curative resection of hepatocellular carcinoma: long-term results of treatment and prognostic factors. (1999) (558)
Development of Hong Kong Liver Cancer staging system with treatment stratification for patients with hepatocellular carcinoma. (2014) (543)
A subpopulation of CD26+ cancer stem cells with metastatic capacity in human colorectal cancer. (2010) (523)
Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. (2013) (522)
Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial. (2014) (513)
Locoregional Therapies for Hepatocellular Carcinoma: A Critical Review From the Surgeon’s Perspective (2002) (414)
Twist Overexpression Correlates with Hepatocellular Carcinoma Metastasis through Induction of Epithelial-Mesenchymal Transition (2006) (410)
Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting. (2010) (378)
Identification of local and circulating cancer stem cells in human liver cancer (2008) (345)
Continuous Improvement of Survival Outcomes of Resection of Hepatocellular Carcinoma: A 20-Year Experience (2011) (333)
The microRNA miR-139 suppresses metastasis and progression of hepatocellular carcinoma by down-regulating Rho-kinase 2. (2011) (291)
Alternatively activated (M2) macrophages promote tumour growth and invasiveness in hepatocellular carcinoma. (2015) (290)
A phase I/II trial of chemoembolization for hepatocellular carcinoma using a novel intra-arterial drug-eluting bead. (2007) (286)
Tumor microvessel density as a predictor of recurrence after resection of hepatocellular carcinoma: a prospective study. (2002) (281)
Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: A randomized phase III trial (2014) (250)
Serum Vascular Endothelial Growth Factor Predicts Venous Invasion in Hepatocellular Carcinoma : A Prospective Study (2001) (246)
Is Hepatic Resection for Large or Multinodular Hepatocellular Carcinoma Justified? Results From a Multi-Institutional Database (2005) (245)
Abdominal Drainage After Hepatic Resection Is Contraindicated in Patients With Chronic Liver Diseases (2004) (224)
External drainage of pancreatic duct with a stent to reduce leakage rate of pancreaticojejunostomy after pancreaticoduodenectomy: a prospective randomized trial. (2008) (223)
Octamer 4 (Oct4) mediates chemotherapeutic drug resistance in liver cancer cells through a potential Oct4–AKT–ATP‐binding cassette G2 pathway (2010) (216)
Hepatectomy for hepatocellular carcinoma: Patient selection and postoperative outcome (2004) (212)
Learning Curve for Radiofrequency Ablation of Liver Tumors: Prospective Analysis of Initial 100 Patients in a Tertiary Institution (2004) (206)
Quantitative correlation of serum levels and tumor expression of vascular endothelial growth factor in patients with hepatocellular carcinoma. (2003) (203)
Prospective Evaluation of Selective Defunctioning Stoma for Low Anterior Resection with Total Mesorectal Excision (1999) (199)
Prevention of pancreatic anastomotic leakage after pancreaticoduodenectomy. (2002) (192)
Recurrence of Hepatitis B-Related Hepatocellular Carcinoma Is Associated With High Viral Load at the Time of Resection (2008) (182)
Interleukin-8 serum levels in patients with hepatocellular carcinoma: correlations with clinicopathological features and prognosis. (2003) (182)
A randomized placebo‐controlled study of long‐acting octreotide for the treatment of advanced hepatocellular carcinoma (2002) (181)
Risk for hepatocellular carcinoma with respect to hepatitis B virus genotypes B/C, specific mutations of enhancer II/core promoter/precore regions and HBV DNA levels (2007) (180)
From Molecular Biology to Targeted Therapies for Hepatocellular Carcinoma: The Future Is Now (2007) (179)
Extended Hepatic Resection for Hepatocellular Carcinoma in Patients with Cirrhosis: Is It Justified? (2002) (177)
Tissue factor expression correlates with tumor angiogenesis and invasiveness in human hepatocellular carcinoma. (2003) (177)
Long-term prognosis after resection of hepatocellular carcinoma associated with hepatitis B-related cirrhosis. (2000) (174)
Difference in Tumor Invasiveness in Cirrhotic Patients With Hepatocellular Carcinoma Fulfilling the Milan Criteria Treated by Resection and Transplantation: Impact on Long-term Survival (2007) (171)
Vascular Changes in Hepatocellular Carcinoma (2008) (167)
Transarterial chemoembolization for inoperable hepatocellular carcinoma and postresection intrahepatic recurrence (2000) (164)
Clinicopathologic features of long-term survivors and disease-free survivors after resection of hepatocellular carcinoma: a study of a prospective cohort. (2001) (158)
Microvessel density, vascular endothelial growth factor and its receptors Flt-1 and Flk-1/KDR in hepatocellular carcinoma. (2001) (158)
External Drainage of Pancreatic Duct With a Stent to Reduce Leakage Rate of Pancreaticojejunostomy After Pancreaticoduodenectomy: A Prospective Randomized Trial (2007) (157)
Phase 2 open‐label study of single‐agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B–endemic Asian population (2009) (155)
Selection criteria for hepatic resection in patients with large hepatocellular carcinoma larger than 10 cm in diameter. (2002) (153)
Long-Term Survival Analysis of Pure Laparoscopic Versus Open Hepatectomy for Hepatocellular Carcinoma in Patients With Cirrhosis: A Single-Center Experience (2013) (144)
Significance of circulating endothelial progenitor cells in hepatocellular carcinoma (2006) (140)
Macrophage migration inhibitory factor: Roles in regulating tumor cell migration and expression of angiogenic factors in hepatocellular carcinoma (2003) (137)
Determination of the molecular relationship between multiple tumour nodules in hepatocellular carcinoma differentiates multicentric origin from intrahepatic metastasis (2003) (136)
Occult hepatitis B infection and HBV replicative activity in patients with cryptogenic cause of hepatocellular carcinoma (2011) (135)
Suppression of Liver Tumor Growth and Metastasis by Adiponectin in Nude Mice through Inhibition of Tumor Angiogenesis and Downregulation of Rho Kinase/IFN-Inducible Protein 10/Matrix Metalloproteinase 9 Signaling (2010) (135)
Correlation of serum basic fibroblast growth factor levels with clinicopathologic features and postoperative recurrence in hepatocellular carcinoma. (2001) (132)
Genomic Profiling of Intrahepatic Cholangiocarcinoma: Refining Prognosis and Identifying Therapeutic Targets (2014) (125)
High Serum Vascular Endothelial Growth Factor Levels Predict Poor Prognosis after Radiofrequency Ablation of Hepatocellular Carcinoma: Importance of Tumor Biomarker in Ablative Therapies (2007) (122)
Comparison of early endoscopic ultrasonography and endoscopic retrograde cholangiopancreatography in the management of acute biliary pancreatitis: a prospective randomized study. (2005) (119)
Ischemia‐reperfusion of small liver remnant promotes liver tumor growth and metastases—Activation of cell invasion and migration pathways (2007) (118)
High serum levels of vascular endothelial growth factor predict poor response to transarterial chemoembolization in hepatocellular carcinoma: a prospective study. (2004) (116)
Signal transducers and activators of transcription 5b activation enhances hepatocellular carcinoma aggressiveness through induction of epithelial-mesenchymal transition. (2006) (115)
High-Intensity Focused Ultrasound for Hepatocellular Carcinoma: A Single-Center Experience (2011) (114)
Impact of antiviral therapy on the survival of patients after major hepatectomy for hepatitis B virus-related hepatocellular carcinoma. (2011) (114)
Treatment strategy for recurrent hepatocellular carcinoma: Salvage transplantation, repeated resection, or radiofrequency ablation? (2013) (113)
Clinicopathological and prognostic significance of serum and tissue Dickkopf‐1 levels in human hepatocellular carcinoma (2011) (113)
Allograft inflammatory factor-1 (AIF-1) is crucial for the survival and pro-inflammatory activity of macrophages. (2005) (112)
PIN1 overexpression and β-catenin gene mutations are distinct oncogenic events in human hepatocellular carcinoma (2004) (109)
An Akt/Hypoxia-Inducible Factor-1α/Platelet-Derived Growth Factor-BB Autocrine Loop Mediates Hypoxia-Induced Chemoresistance in Liver Cancer Cells and Tumorigenic Hepatic Progenitor Cells (2009) (109)
Circulating Oncometabolite 2-Hydroxyglutarate Is a Potential Surrogate Biomarker in Patients with Isocitrate Dehydrogenase-Mutant Intrahepatic Cholangiocarcinoma (2014) (109)
Microvascular Invasion Does Not Predict Long-Term Survival in Hepatocellular Carcinoma up to 2 cm: Reappraisal of the Staging System for Solitary Tumors (2013) (108)
The significance of early alpha-fetoprotein level changes in predicting clinical and survival benefits in advanced hepatocellular carcinoma patients receiving sorafenib. (2011) (107)
Current techniques of liver transection. (2007) (107)
Aggressive management of patients with extrahepatic and intrahepatic recurrences of hepatocellular carcinoma by combined resection and locoregional therapy. (2002) (106)
Over-Expression of miR-106b Promotes Cell Migration and Metastasis in Hepatocellular Carcinoma by Activating Epithelial-Mesenchymal Transition Process (2013) (103)
Prognosis After Hepatic Resection for Stage IVA Hepatocellular Carcinoma: A Need for Reclassification (2003) (102)
A prospective longitudinal study of quality of life after resection of hepatocellular carcinoma. (2001) (102)
Hepatic resection for combined hepatocellular and cholangiocarcinoma. (2003) (100)
Survival Analysis of Re-resection Versus Radiofrequency Ablation for Intrahepatic Recurrence After Hepatectomy for Hepatocellular Carcinoma (2011) (99)
Both antiangiogenesis- and angiogenesis-independent effects are responsible for hepatocellular carcinoma growth arrest by tyrosine kinase inhibitor PTK787/ZK222584. (2005) (98)
FTY720: A Promising Agent for Treatment of Metastatic Hepatocellular Carcinoma (2005) (97)
The Enhanced Metastatic Potential of Hepatocellular Carcinoma (HCC) Cells with Sorafenib Resistance (2013) (96)
Evaluation of the new AJCC/UICC staging system for hepatocellular carcinoma after hepatic resection in Chinese patients. (2003) (96)
Identification of brain-derived neurotrophic factor as a novel functional protein in hepatocellular carcinoma. (2005) (96)
Biology of Hepatocellular Carcinoma (2008) (94)
1398 BRIVANIB VERSUS PLACEBO IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA (HCC) WHO FAILED OR WERE INTOLERANT TO SORAFENIB: RESULTS FROM THE PHASE 3 BRISK-PS STUDY (2012) (92)
Surgical Outcomes in Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombosis (2014) (91)
Treatment of advanced hepatocellular carcinoma with tamoxifen and the correlation with expression of hormone receptors: a prospective randomized study (2000) (90)
Clinical Significance of Thrombospondin 1 Expression in Hepatocellular Carcinoma (2004) (90)
Tuberculosis of pancreas and peripancreatic lymph nodes in immunocompetent patients: experience from China. (2003) (90)
Phase III HEAT Study Adding Lyso-Thermosensitive Liposomal Doxorubicin to Radiofrequency Ablation in Patients with Unresectable Hepatocellular Carcinoma Lesions (2017) (87)
Effects of a novel immunomodulating agent, FTY720, on tumor growth and angiogenesis in hepatocellular carcinoma (2005) (87)
Pancreaticoduodenectomy with En Bloc Portal Vein Resection for Pancreatic Carcinoma with Suspected Portal Vein Involvement (2004) (87)
A Garlic Derivative, S-allylcysteine (SAC), Suppresses Proliferation and Metastasis of Hepatocellular Carcinoma (2012) (85)
A Phase II Study of the Efficacy and Safety of the Combination Therapy of the MEK Inhibitor Refametinib (BAY 86-9766) Plus Sorafenib for Asian Patients with Unresectable Hepatocellular Carcinoma (2014) (85)
Choledochal cysts in adults. (2002) (84)
Quantification of hepatitis B virus covalently closed circular DNA in patients with hepatocellular carcinoma. (2006) (83)
Sustained disease remission after spontaneous HBeAg seroconversion is associated with reduction in fibrosis progression in chronic hepatitis B Chinese patients (2007) (83)
A phase 1 dose-escalating study of pegylated recombinant human arginase 1 (Peg-rhArg1) in patients with advanced hepatocellular carcinoma (2012) (83)
Clinical Significance of Angiogenesis in Gastrointestinal Cancers: A Target for Novel Prognostic and Therapeutic Approaches (2003) (82)
Surgery for Intermediate and Advanced Hepatocellular Carcinoma: A Consensus Report from the 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2014) (2016) (81)
TSC1/2 mutations define a molecular subset of HCC with aggressive behaviour and treatment implication (2016) (81)
Phase I Dose-Finding Study of Pazopanib in Hepatocellular Carcinoma: Evaluation of Early Efficacy, Pharmacokinetics, and Pharmacodynamics (2011) (80)
Management of advanced hepatocellular carcinoma in the era of targeted therapy (2009) (79)
Effectiveness of radiofrequency ablation for hepatocellular carcinomas larger than 3 cm in diameter. (2004) (78)
Tumor cyclooxygenase-2 levels correlate with tumor invasiveness in human hepatocellular carcinoma. (2005) (77)
Hepatocellular carcinoma in the elderly: results of surgical and nonsurgical management (1999) (77)
Can positron emission tomography with the dual tracers [11C]acetate and [18F]fludeoxyglucose predict microvascular invasion in hepatocellular carcinoma? (2011) (76)
Evaluation of the seventh edition of the American Joint Committee on Cancer tumour-node-metastasis (TNM) staging system for patients undergoing curative resection of hepatocellular carcinoma: implications for the development of a refined staging system. (2013) (75)
Changing Paradigm in the Management of Hepatocellular Carcinoma Improves the Survival Benefit of Early Detection by Screening (2008) (74)
Notch1‐Snail1‐E‐cadherin pathway in metastatic hepatocellular carcinoma (2012) (74)
Gold(III) compound is a novel chemocytotoxic agent for hepatocellular carcinoma (2006) (74)
Management of carcinoma of the gallbladder: A single‐institution experience in 16 years (2008) (73)
Radiofrequency ablation for malignant liver tumor. (2005) (73)
Liver Cancer Working Group report. (2010) (72)
Inhibition of mTOR enhances chemosensitivity in hepatocellular carcinoma. (2009) (71)
Randomized, open‐label phase 2 study comparing frontline dovitinib versus sorafenib in patients with advanced hepatocellular carcinoma (2016) (71)
Phase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinoma. (2013) (70)
Re‐evaluating transarterial chemoembolization for the treatment of Hepatocellular Carcinoma: Consensus recommendations and review by an International Expert Panel (2014) (70)
Evolution of systemic therapy of advanced hepatocellular carcinoma. (2008) (69)
Brain-Derived Neurotrophic Factor Promotes Tumorigenesis via Induction of Neovascularization: Implication in Hepatocellular Carcinoma (2011) (67)
Liver resection using a saline-linked radiofrequency dissecting sealer for transection of the liver. (2005) (67)
Overexpression of matrix metalloproteinase-12 (MMP-12) correlates with poor prognosis of hepatocellular carcinoma. (2011) (66)
Genome-Wide Association Study of Hepatocellular Carcinoma in Southern Chinese Patients with Chronic Hepatitis B Virus Infection (2011) (65)
Oncoproteomics of hepatocellular carcinoma: from cancer markers' discovery to functional pathways (2007) (65)
The use of single‐agent sorafenib in the treatment of advanced hepatocellular carcinoma patients with underlying Child‐Pugh B liver cirrhosis (2012) (65)
ALPPS Versus Portal Vein Embolization for Hepatitis-related Hepatocellular Carcinoma (2019) (64)
A new prognostic score system in patients with advanced hepatocellular carcinoma not amendable to locoregional therapy (2008) (64)
Regulation of Angiogenesis by Id-1 through Hypoxia-Inducible Factor-1α–Mediated Vascular Endothelial Growth Factor Up-regulation in Hepatocellular Carcinoma (2006) (63)
Preliminary efficacy, safety, pharmacokinetics, pharmacodynamics and quality of life study of pegylated recombinant human arginase 1 in patients with advanced hepatocellular carcinoma (2015) (63)
Perioperative and long-term outcome of major hepatic resection for small solitary hepatocellular carcinoma in patients with cirrhosis. (2003) (62)
Survival analysis of patients with transplantable recurrent hepatocellular carcinoma: implications for salvage liver transplant. (2008) (62)
Outcome of laparoscopic versus open hepatectomy for colorectal liver metastases (2013) (62)
The outcomes and safety of single-agent sorafenib in the treatment of elderly patients with advanced hepatocellular carcinoma (HCC). (2011) (61)
Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study. (2017) (60)
Inhibition of Stat3 activity by YC-1 enhances chemo-sensitivity in hepatocellular carcinoma (2007) (59)
Phase II study of bevacizumab and erlotinib in the treatment of advanced hepatocellular carcinoma patients with sorafenib-refractory disease (2012) (59)
STORM: A phase III randomized, double-blind, placebo-controlled trial of adjuvant sorafenib after resection or ablation to prevent recurrence of hepatocellular carcinoma (HCC) (2014) (58)
Octamer 4 ( Oct 4 ) Mediates Chemotherapeutic Drug Resistance in Liver Cancer Cells Through a Potential Oct 4 – AKT – ATP-Binding Cassette G 2 Pathway (2010) (58)
Comparison of percutaneous and surgical approaches for radiofrequency ablation of small and medium hepatocellular carcinoma. (2007) (58)
Inflammatory Cecal Masses in Patients Presenting with Appendicitis (1999) (57)
Porcine liver: morphologic characteristics and cell viability at experimental radiofrequency ablation with internally cooled electrodes. (2005) (57)
Clinicopathological and prognostic implications of endoglin (CD105) expression in hepatocellular carcinoma and its adjacent non-tumorous liver. (2005) (57)
Assessment of hepatic reserve for indication of hepatic resection: how I do it. (2005) (56)
Comparison of Systemic Responses of Radiofrequency Ablation, Cryotherapy, and Surgical Resection in a Porcine Liver Model (2004) (55)
Outcomes of Patients with Hepatocellular Carcinoma Presenting with Variceal Bleeding (2004) (51)
Hepatic angiomyolipoma. (2003) (51)
Hepatic resection for bilobar hepatocellular carcinoma: is it justified? (2003) (51)
Rac Activation Is Associated with Hepatocellular Carcinoma Metastasis by Up-regulation of Vascular Endothelial Growth Factor Expression (2006) (50)
Significance of the Rac signaling pathway in HCC cell motility: implications for a new therapeutic target. (2005) (50)
High-intensity focused ultrasound ablation: an effective bridging therapy for hepatocellular carcinoma patients. (2013) (49)
Over-expression of Id-1 induces cell proliferation in hepatocellular carcinoma through inactivation of p16INK4a/RB pathway. (2003) (49)
Cancer stem cell as a potential therapeutic target in hepatocellular carcinoma. (2012) (49)
Suppression of tumorigenesis and metastasis of hepatocellular carcinoma by shRNA interference targeting on homeoprotein Six1 (2010) (48)
Is primary resection and salvage transplantation for hepatocellular carcinoma a reasonable strategy? (2004) (48)
Recent Advances in the Prevention of Hepatocellular Carcinoma Recurrence (2014) (48)
Does diabetes mellitus influence the perioperative outcome or long term prognosis after resection of hepatocellular carcinoma? (2002) (47)
Phase I study of the safety and efficacy of INC280 in patients with advanced MET-dependent solid tumors. (2014) (46)
Proline-Rich Tyrosine Kinase 2 (Pyk2) Promotes Cell Motility of Hepatocellular Carcinoma through Induction of Epithelial to Mesenchymal Transition (2011) (45)
Results of percutaneous transhepatic cholecystostomy for high surgical risk patients with acute cholecystitis (2010) (44)
Hong Kong Consensus Recommendations on the Management of Hepatocellular Carcinoma (2015) (43)
Phase 1 study of capmatinib in MET‐positive solid tumor patients: Dose escalation and expansion of selected cohorts (2019) (43)
The outcomes of elderly patients with hepatocellular carcinoma treated with transarterial chemoembolization (2009) (42)
Feasibility of Laparoscopic Re-resection for Patients with Recurrent Hepatocellular Carcinoma (2014) (42)
Radiofrequency Ablation for Subcapsular Hepatocellular Carcinoma (2004) (41)
Differentiating Early and Late Recurrences After Resection of HCC in Cirrhotic Patients: Implications on Surveillance, Prevention, and Treatment Strategies (2009) (41)
Safety of ALPPS Procedure by the Anterior Approach for Hepatocellular Carcinoma. (2016) (41)
EVOLVE-1: Phase 3 study of everolimus for advanced HCC that progressed during or after sorafenib. (2014) (40)
Comparative proteomic analysis of mouse livers from embryo to adult reveals an association with progression of hepatocellular carcinoma (2008) (40)
Outcome of transarterial chemoembolization in patients with inoperable hepatocellular carcinoma eligible for radiofrequency ablation. (2005) (40)
Laparoscopic versus open liver resection for elderly patients with malignant liver tumors: A single‐center experience (2014) (40)
Resection prior to liver transplantation for hepatocellular carcinoma: A strategy of optimizing the role of resection and transplantation in cirrhotic patients with preserved liver function (2004) (39)
Desensitization of T lymphocyte function by CXCR3 ligands in human hepatocellular carcinoma. (2005) (39)
Clinical relevance and therapeutic potential of angiopoietin-like protein 4 in hepatocellular carcinoma (2014) (39)
Chemokine receptors support infiltration of lymphocyte subpopulations in human hepatocellular carcinoma. (2005) (39)
Liver Intestine-Cadherin (CDH17) Haplotype Is Associated with Increased Risk of Hepatocellular Carcinoma (2006) (38)
Suppression of hypoxia inducible factor-1α (HIF-1α) by YC-1 is dependent on murine double minute 2 (Mdm2) (2006) (38)
Pancreaticoduodenectomy with vascular reconstruction for adenocarcinoma of the pancreas with borderline resectability. (2014) (37)
A Phase I/II Multicenter Study of Single-Agent Foretinib as First-Line Therapy in Patients with Advanced Hepatocellular Carcinoma (2016) (37)
Osteopontin Overexpression Induced Tumor Progression and Chemoresistance to Oxaliplatin through Induction of Stem-Like Properties in Human Colorectal Cancer (2015) (36)
The Role of Proline Rich Tyrosine Kinase 2 (Pyk2) on Cisplatin Resistance in Hepatocellular Carcinoma (2011) (35)
Post-Operative Plasma Osteopontin Predicts Distant Metastasis in Human Colorectal Cancer (2015) (34)
Pure Laparoscopic Versus Open Left Lateral Sectionectomy for Hepatocellular Carcinoma: A Single-Center Experience (2015) (34)
PTK787/ZK22258 attenuates stellate cell activation and hepatic fibrosis in vivo by inhibiting VEGF signaling (2009) (34)
Use of Liver Stiffness Measurement for Liver Resection Surgery: Correlation with Indocyanine Green Clearance Testing and Post-Operative Outcome (2013) (33)
Granulin–Epithelin Precursor Renders Hepatocellular Carcinoma Cells Resistant to Natural Killer Cytotoxicity (2014) (33)
Aberrant Polo-Like Kinase 1-Cdc25A Pathway in Metastatic Hepatocellular Carcinoma (2008) (33)
Thoracoabdominal approach for right-sided hepatic resection for hepatocellular carcinoma. (2003) (33)
Biomarkers for predicting future metastasis of human gastrointestinal tumors (2013) (33)
Antiinflammatory properties of IL‐10 rescue small‐for‐size liver grafts (2007) (32)
Identification of Transmembrane Protein 98 as a Novel Chemoresistance-Conferring Gene in Hepatocellular Carcinoma (2014) (31)
Anti-tumor efficacy of a recombinant human arginase in human hepatocellular carcinoma. (2012) (30)
A phase I/II study of foretinib, an oral multikinase inhibitor targeting MET, RON, AXL, TIE-2, and VEGFR in advanced hepatocellular carcinoma (HCC). (2012) (30)
The kringle 1 domain of hepatocyte growth factor has antiangiogenic and antitumor cell effects on hepatocellular carcinoma. (2008) (30)
Impact of preoperative fine-needle aspiration cytologic examination on clinical outcome in patients with hepatocellular carcinoma in a tertiary referral center. (2004) (30)
Comparable survival in patients with unresectable hepatocellular carcinoma treated by radiofrequency ablation or transarterial chemoembolization. (2006) (30)
Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): Analysis of patients with elevated {alpha}-fetoprotein (AFP) from the randomized phase III REACH study. (2015) (30)
Platelet activation during tumor development, the potential role of BDNF-TrkB autocrine loop. (2006) (30)
Suppression of hypoxia inducible factor-1alpha (HIF-1alpha) by YC-1 is dependent on murine double minute 2 (Mdm2). (2006) (29)
Marked suppression of tumor growth by FTY720 in a rat liver tumor model: the significance of down-regulation of cell survival Akt pathway. (2007) (28)
Efficacy and Tolerability of Low-Dose Thalidomide as First-Line Systemic Treatment of Patients with Advanced Hepatocellular Carcinoma (2007) (28)
Recent advances in techniques of liver resection. (2004) (28)
Survival analysis of high‐intensity focused ultrasound therapy vs. transarterial chemoembolization for unresectable hepatocellular carcinomas (2014) (27)
Inflammatory pseudotumor of the liver in association with a gastrointestinal stromal tumor: a case report. (2004) (26)
Integrative biomarker analyses indicate etiological variations in hepatocellular carcinoma. (2016) (26)
Pancreatic-induced intramural duodenal haematoma. (2008) (26)
Survival analysis of transarterial radioembolization with yttrium-90 for hepatocellular carcinoma patients with HBV infection. (2014) (26)
Digestive cancer management in Asia: Position statements: A report on GI Oncology Summit in 2011 (2012) (25)
Comparison of systemic responses of radiofrequency ablation, cryotherapy and surgical resection in a porcine liver model (2004) (25)
Safety limit of large-volume hepatic radiofrequency ablation in a rat model. (2006) (25)
Establishment and characterization of a novel primary hepatocellular carcinoma cell line with metastatic ability in vivo (2014) (25)
Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: an analysis of the phase 3 REACH study (2018) (25)
Reduced Expression of Chemokine Receptors on Peripheral Blood Lymphocytes in Patients with Hepatocellular Carcinoma (2004) (25)
Therapeutic efficacy of Traditional Chinese Medicine 319 recipe on hepatic fibrosis induced by carbon tetrachloride in rats. (2009) (24)
Decreasing the pancreatic leak rate after pancreaticoduodenectomy. (2008) (24)
High doses of tyrosine kinase inhibitor PTK787 enhance the efficacy of ischemic hypoxia for the treatment of hepatocellular carcinoma: dual effects on cancer cell and angiogenesis (2006) (24)
Risk Factors and Post-Resection Independent Predictive Score for the Recurrence of Hepatitis B-Related Hepatocellular Carcinoma (2016) (24)
LBA16RAMUCIRUMAB (RAM) AS SECOND-LINE TREATMENT IN PATIENTS (PTS) WITH ADVANCED HEPATOCELLULAR CARCINOMA (HCC) FOLLOWING FIRST-LINE THERAPY WITH SORAFENIB: RESULTS FROM THE RANDOMIZED PHASE III REACH STUDY (2014) (23)
Portal vein thrombosis after radiofrequency ablation for recurrent hepatocellular carcinoma. (2003) (22)
A phase I study of pazopanib in patients with advanced hepatocellular carcinoma. (2009) (22)
The Clinicopathological Significance of miR-133a in Colorectal Cancer (2014) (22)
Tolerance of radiofrequency ablation by patients of hepatocellular carcinoma. (2009) (22)
Cardiotrophin‐1 enhances regeneration of cirrhotic liver remnant after hepatectomy through promotion of angiogenesis and cell proliferation (2008) (22)
A case of laparoscopic hepatectomy for recurrent hepatocellular carcinoma. (2010) (21)
Trans‐arterial chemo‐embolization is safe and effective for elderly advanced hepatocellular carcinoma patients: results from an international database (2014) (21)
Deleted in liver cancer 1 isoforms are distinctly expressed in human tissues, functionally different and under differential transcriptional regulation in hepatocellular carcinoma (2010) (21)
Significance of the serum brain-derived neurotrophic factor and platelets in hepatocellular carcinoma. (2006) (21)
Phase I study of everolimus in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC). (2011) (20)
Antisecretory agents for prevention of post-ERCP pancreatitis: rationale for use and clinical results. (2003) (20)
Randomized phase II trial of intravenous RO5137382/GC33 at 1600 mg every other week and placebo in previously treated patients with unresectable advanced hepatocellular carcinoma (HCC; NCT01507168). (2014) (20)
Expression of ankyrin repeat and SOCS box containing 4 (ASB4) confers migration and invasion properties of hepatocellular carcinoma cells. (2014) (20)
Value of live donor liver transplantation experience in major hepatectomy for hepatocellular carcinoma. (2003) (19)
Disruption of p53-p21/WAF1 cell cycle pathway contributes to progression and worse clinical outcome of hepatocellular carcinoma. (2004) (19)
Acute intraoperative hemolysis and hemoglobinuria during radiofrequency ablation of hepatocellular carcinoma. (2003) (19)
Management of Spontaneously Ruptured Hepatocellular Carcinomas in the Radiofrequency Ablation Era (2014) (19)
Optimal Initial Treatment for Early Hepatocellular Carcinoma in Patients with Preserved Liver Function: Transplantation or Resection? (2007) (18)
Synchronous resections of primary colorectal tumor and liver metastasis by laparoscopic approach. (2013) (18)
Clinical significance of serum vascular cell adhesion molecule-1 levels in patients with hepatocellular carcinoma. (2004) (18)
Modified Anterior Approach for the ALPPS Procedure: How We Do It (2015) (18)
Therapeutic potential of cardiotrophin 1 in fulminant hepatic failure: dual roles in antiapoptosis and cell repair. (2006) (17)
Dissecting EASL/AASLD Recommendations With a More Careful Knife: A Comment on "Surgical Misinterpretation" of the BCLC Staging System. (2015) (16)
Comparison of Survival Outcomes Between Right Posterior Sectionectomy and Right Hepatectomy for Hepatocellular Carcinoma in Cirrhotic Liver: A Single-Centre Experience (2015) (16)
Suppression of Slit3 induces tumor proliferation and chemoresistance in hepatocellular carcinoma through activation of GSK3β/β-catenin pathway (2018) (16)
A multicenter phase II study of sorafenib, capecitabine, and oxaliplatin (SECOX) in patients with advanced hepatocellular carcinoma: Final results of Hong Kong-Singapore Hepatocellular Carcinoma Research Collaborative Group study. (2013) (15)
Intraoperative Iatrogenic Rupture of Hepatocellular Carcinoma (2002) (15)
p27Kip1 Promotes Migration of Metastatic Hepatocellular Carcinoma Cells (2008) (15)
Molecular targeted therapy of advanced hepatocellular carcinoma beyond sorafenib (2010) (14)
Analysis of long‐term survival after hepatectomy for isolated liver metastasis of gastrointestinal stromal tumour (2014) (14)
Evaluation of patupilone as monotherapy in patients with advanced hepatocellular carcinoma (HCC) (2007) (14)
Outcomes of central bisectionectomy for hepatocellular carcinoma. (2013) (14)
Safety and efficacy of radiofrequency ablation for periductal hepatocellular carcinoma with intraductal cooling of the central bile duct. (2008) (14)
Current treatment strategy for hepatocellular carcinoma. (2007) (13)
Efficacy and tolerability of single agent sorafenib in poor risk advanced hepatocellular carcinoma patients (2008) (13)
Primary perivascular epithelioid cell tumour (PEComa) of the liver (2013) (13)
A phase II trial of MEK inhibitor BAY 86-9766 in combination with sorafenib as first-line systemic treatment for patients with unresectable hepatocellular carcinoma (HCC). (2012) (13)
Does diabetes mellitus influence the perioperative outcome or long term prognosis after resection of hepatocellular carcinoma (2002) (13)
The Roles of Lipocalin-2 in Small-for-Size Fatty Liver Graft Injury (2014) (12)
Emergence of CD26+ Cancer Stem Cells with Metastatic Properties in Colorectal Carcinogenesis (2017) (12)
Nine-year experience of doxorubicin-eluting beads chemoembolization for hepatocellular carcinoma. (2016) (11)
Radiofrequency Ablation Combined with Resection Enhances Chance for Curative Treatment of Hepatocellular Carcinoma (2007) (11)
Brunner's gland adenoma: unusual cause of duodenal haemorrhage and obstruction. (2013) (10)
Long-term survival after intraluminal brachytherapy for inoperable hilar cholangiocarcinoma: a case report. (2005) (10)
Re‐resection for metachronous primary hepatocellular carcinoma: is it justified? (2012) (10)
Survival outcome of re‐resection for recurrent liver metastases of colorectal cancer: a retrospective study (2014) (10)
Reply to Letter: "Long-term Survival Analysis of Pure Laparoscopic Versus Open Hepatectomy for Hepatocellular Carcinoma in Patients With Cirrhosis: A Single-center Experience". (2015) (9)
Advanced pancreatic cancer: flourishing novel approaches in the era of biological therapy. (2014) (9)
Repeated resections of extrahepatic metastases after hepatic resection: an aggressive approach to hepatocellular carcinoma. (2004) (9)
Phase II study of front-line dovitinib (TKI258) versus sorafenib in patients (Pts) with advanced hepatocellular carcinoma (HCC). (2015) (8)
665 A PHASE I/II STUDY OF FORETINIB, AN ORAL MULTIKINASE INHIBITOR TARGETING MET, RON, AXL, TIE-2 AND VEGFR IN ADVANCED HEPATOCELLULAR CARCINOMA (HCC) (2011) (8)
Current role of laparoscopic surgery for liver malignancies. (2007) (8)
High-intensity focused ultrasound as a treatment for colorectal liver metastasis in difficult position (2011) (8)
A phase I study of recombinant human arginase I (rhArgI) for patients with advanced hepatocellular carcinoma (2010) (7)
Duodenopleural fistula formation after percutaneous radiofrequency ablation for recurrent hepatocellular carcinoma. (2007) (7)
Radiofrequency ablation for controlling iatrogenic splenic injury (2009) (7)
Retrospective study of metachronous lung metastases from primary hepatocellular carcinoma (2016) (6)
Molecular predictors of recurrence prevention with sorafenib as adjuvant therapy in hepatocellular carcinoma: Biomarker study of the STORM phase III trial (2017) (6)
Overexpression of Pin1 and rho signaling partners correlates with metastatic behavior and poor recurrence-free survival of hepatocellular carcinoma patients (2019) (6)
Liver Transplantation for Solitary Hepatocellular Carcinoma Less than 3 cm in Diameter in Child A Cirrhosis (2007) (6)
Gastrointestinal tumors, non-colorectal (2012) (6)
Induction of long‐term liver allograft survival by delayed immunosuppression is dependent on interleukin‐10 (2007) (6)
Corrigendum to 'Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study' [Eur J Canc 81 (2017) 17-25]. (2018) (5)
1206 Phase I study of Pazopanib (PAZ) in Hepatocellular Carcinoma (HCC): evaluation of clinical activity, Pharmacokinetics (PK), and Dynamic Contrast Enhanced MRI (DCE-MRI) (2009) (5)
Preliminary efficacy, safety, pharmacokinetics, pharmacodynamics, and quality of life study of pegylated recombinant human arginase 1 in patients with advanced hepatocellular carcinoma. (2014) (5)
Angiogenesis in Hepatocellular Carcinoma (2000) (4)
Long-Term Disease-Free Survival After Resection of Hepatocellular Carcinoma: Both Tumor Behavior and Surgeon’s Performance Are Important Determinants (2003) (4)
Improved anterior hepatic transection for isolated hepatocellular carcinoma in the caudate. (2014) (4)
LBA17RANDOMISED STUDY OF AXITINIB (AXI) PLUS BEST SUPPORTIVE CARE (BSC) VERSUS PLACEBO (PBO) PLUS BSC IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA (HCC) FOLLOWING PRIOR ANTIANGIOGENIC THERAPY (2014) (4)
Long-Term P rognosis A fter R esection o f H epatocellular Carcinoma A ssociated W ith H epatitis B -Related C irrhosis (2000) (4)
Efficacy and safety of single-agent sunitinib in treating patients with advanced hepatocelluar carcinoma after sorafenib failure: A prospective, open-label, phase II study. (2011) (4)
Corrigendum to "Alternatively activated (M2) macrophages promote tumour growth and invasiveness in hepatocellular carcinoma" [J Hepatol 2015;62:607-616]. (2016) (4)
2337 Ramucirumab (RAM) as a second-line treatment in patients with advanced hepatocellular carcinoma (HCC) following first-line therapy with sorafenib in the randomized phase III REACH study: Analysis of alpha-fetoprotein (AFP) kinetics during treatment (2015) (4)
Ramucirumab as Second-Line Treatment in Patients with Advanced Hepatocellular Carcinoma: Analysis of Reach Patients by Albumin-Bilirubin (ALBI) Grade (2016) (3)
Clinical implications of altered energy metabolism in patients with cirrhosis. (2002) (3)
Significance of viral status on prognosis after resection of hepatitis B virus related hepatocellular carcinoma. (2007) (3)
Clinicopathologic and prognostic significance of the histologic activity of noncancerous liver tissue in hepatitis B virus-associated hepatocellular carcinoma. (2002) (3)
810 Improved Long-Term Survival After Major Resection for Hepatocellular Carcinoma: A Multicenter Analysis Based on a New Definition of Major Hepatectomy (2012) (2)
O-005Ramucirumab (RAM) as second-Line treatment in patients with advanced hepatocellular carcinoma (HCC) following first-line therapy with sorafenib: comprehensive results from the randomized phase III REACH study (2015) (2)
The Hong Kong consensus statements on unresectable hepatocellular carcinoma: narrative review and update for 2021 (2021) (2)
Hepatic Resection for Bilobar Hepatocellular Carcinoma (2015) (2)
Significance of local and circulating cancer stem cells in human liver cancer (2008) (2)
Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome (PFO) results from the phase 3 REACH study. (2015) (2)
Clinical Significance of Angiogenesis in Hepatocellular Carcinoma (2003) (1)
Prognostic Impact of Diabetes Mellitus on Patients with Hepatocellular Carcinoma (2004) (1)
An unusual cause of epigastric pain. (2013) (1)
Efficacy and tolerability of sorafenib in elderly patients with advanced hepatocellular carcinoma. (2010) (1)
Does hepatitis B seroconversion affect survival outcome in patients with hepatitis B related hepatocellular carcinoma? (2016) (1)
Preoperative serum vascular endothelial growth factor predicts venous invasion in hepatocellular carcinoma: a prospective study (Invited Lecture) (2000) (1)
The use of single-agent sorafenib in the treatment of patients with advanced hepatocellular carcinoma with underlying Child-Pugh B liver cirrhosis. (2011) (1)
Title Clinical relevance and therapeutic potential of angiopoietin-likeprotein 4 in hepatocellular carcinoma (2014) (1)
THE POTENTIAL ROLE OF ALLOGRAFT INFLAMMATORY FACTOR 1 (AIF-1) IN MACROPHAGE ACTIVATION IN SMALL-FOR-SIZE LIVER TRANSPLANTATION (2004) (1)
Recent advances in management of hepatocellular carcinoma (2013) (1)
Suppression of hypoxia inducible factor-1 a ( HIF-1 a ) by YC-1 is dependent on murine double minute 2 ( Mdm 2 ) q (2006) (1)
1030 TRANS-ARTERIAL CHEMO-EMBOLIZATION (TACE) IS SAFE AND EFFICIENT FOR ELDERLY PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA (HCC): RESULTS FROM AN INTERNATIONAL META-DATABASE (2012) (1)
Maximal host tolerance to large-volume hepatic radiofrequency ablation in a rat model (2004) (1)
Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2016): Advancing HCC Management Through Multi-Disciplinary Approach 7th Meeting, Hong Kong, July 2016: Abstracts (2016) (1)
Title Proline-rich tyrosine kinase 2 ( Pyk 2 ) promotes cell motility of hepatocellular carcinoma through induction of epithelial to mesenchymal transition (2011) (0)
Title Desensitization of T lymphocyte function by CXCR3 ligands in human hepatocellular carcinoma (2015) (0)
382 Quantitation of HBV covalently closed circular DNA (HBV CCC DNA) in HCC patients (2004) (0)
Suppression of inducible factor-1 α (HIF-1 α ) by is dependent on double minute 2 (Mdm2) (2006) (0)
Title High-intensity focused ultrasound for hepatocellular carcinoma : A single-center experience (2011) (0)
ALPPS for large hepatocellular carcinoma by the anterior approach (2016) (0)
An open-label, randomized phase II study comparing first-line treatment with dovitinib (TKI258) versus sorafenib in patients with advanced hepatocellular carcinoma. (2012) (0)
Recent advances and controversies in surgical management of liver diseases: summary of liver sessions of 7th World Congress of IHPBA 2006. (2007) (0)
High intensity focused ultrasound therapy: a new treatment on the horizon for hepatocellular carcinoma (2011) (0)
Treatment strategy of hepatocellular carcinoma located in right posterior section in patients with liver cirrhosis: right hepatectomy vs right posterior sectionectomy- a case matched single centre experience (2016) (0)
Cancer Therapy : Clinical APhase II Study of theEf fi cacy andSafety of theCombination Therapy of theMEK Inhibitor Refametinib ( BAY 86-9766 ) Plus Sorafenib for Asian Patients with Unresectable Hepatocellular Carcinoma (2014) (0)
Identiﬁcation of Local and Circulating Cancer Stem Cells in Human Liver Cancer (2008) (0)
59 POSTER Adiponectin as a novel therapy for the suppression of liver cancer growth and metastasis (2006) (0)
Subject Index Vol. 25, 2007 (2007) (0)
Title TSC 1 / 2 mutations define a molecular subset of HCC withaggressive behaviour and treatment implication (2017) (0)
Title Differentiating early and late recurrences after resection of HCC in cirrhotic patients : Implications on surveillance , prevention , and treatment strategies (2009) (0)
Title Radiofrequency ablation for controlling iatrogenic splenic injury (2010) (0)
Title Emergence of CD 26 + cancer stem cells with metastaticproperties in colorectal carcinogenesis (2017) (0)
Title Clinical significance of serum vascular cell adhesion molecule-1 levels in patients with hepatocellular carcinoma (2004) (0)
[485] ROLE OF HBV GENOTYPES, CORE PROMOTER/PRECORE MUTATIONS AND HBVDNA LEVELS ON HEPATOCARCINOGENESIS (2007) (0)
Comparison of radiofrequency ablation and hepatic re-resection for intrahepatic recurrent hepatocellular carcinoma (2006) (0)
INDUCTION OF DONOR-SPECIFIC TRANSPLANTATION TOLERANCE BY ALLOANTIGEN-PRIMED MONOCYTE- DERIVED PROGENITOR CELLS COMBINED WITH LOW- DOSE IMMUNOSUPPRESSION: 1497 (2008) (0)
Systemic Management of Advanced Hepatocellular Carcinoma Patients: The Role of Multi-Targeted Anti-Angiogenic Inhibitors (2012) (0)
Resection of hepatocellular carcinoma after combined treatment with transarterial chemoembolization and sorafenib: a case report and literature review (2015) (0)
Blockade of VEGF/VEGFR pathway enhances chemo-sensitivity in hepatocellular carcinoma (2007) (0)
Title Management of spontaneously ruptured hepatocellularcarcinomas in the radiofrequency ablation era (2014) (0)
Title Page / Table of Contents (2016) (0)
157 POSTER Combination therapy for liver tumor growth and metastasis by low dose rapamycin and FTY720 (2006) (0)
The potential role of early-phase graft injury in induction of late-phase chemoresistance after liver transplantation (2010) (0)
Randomized phase II trial of TACE plus everolimus as first-line therapy in localized unresectable hepatocellular carcinoma (HCC): The TRACER trial. (2012) (0)
Right atrial thrombosis complicating Hickman catheter placement: A case report and literature review (2000) (0)
Title Synchronous resections of primary colorectal tumor and livermetastasis by laparoscopic approach (2013) (0)
Subject Index Vol. 72, Suppl. 1, 2007 (2007) (0)
Title Tumor cyclooxygenase-2 levels correlate with tumorinvasiveness in human hepatocellular carcinoma (2014) (0)
Circulating oncometabolite 2-hydroxyglutarate (2HG) as a potential surrogate biomarker in patients with isocitrate dehydrogenase mutant (IDHm) intrahepatic cholangiocarcinoma (ICC). (2013) (0)
4632 Management of gallstone cholangitis in the era of laparoscopic cholecystectomy. (2000) (0)
Title Osteopontin overexpression induced tumor progression and chemoresistance to oxaliplatin through induction of stem-like properties in human colorectal cancer (2015) (0)
Management o f S pontaneous R upture o f H epatocellular Carcinoma: S ingle-Center E xperience (2001) (0)
Contents Vol. 25, 2007 (2007) (0)
Significance of proline rich tyrosine kinase 2 (Pyk2) in epithelial-mesenchymal transition (2007) (0)
AOSOP3 Combination of bevacizumab and erlotinib in the treatment of patients with advanced hepatocellular carcinoma with sorafenib-refractory disease: Results of a pilot phase II study (2012) (0)
Upper GI 21 (2009) (0)
FTY 720 : APromising Agent for Treatment ofMetastatic Hepatocellular Carcinoma (2005) (0)
Imaging , Diagnosis , Prognosis CirculatingOncometabolite 2-Hydroxyglutarate Is aPotential Surrogate Biomarker in Patients with Isocitrate Dehydrogenase-Mutant Intrahepatic Cholangiocarcinoma (2014) (0)
Abstract 4389:TSC1/2mutations define a molecular subset of HCC with aggressive behavior and treatment implication (2017) (0)
Resection of Hepatocellular Carcinoma (2009) (0)
Title Radiofrequency ablation combined with resection enhanceschance for curative treatment of hepatocellular carcinoma (2007) (0)
A Framework Is Required to Reduce Publication Bias The Academic Surgeon's View (2010) (0)
A new prognostic classification scheme with treatment guidelines for Asian patients with hepatocellular carcinoma (HCC): The Hong Kong Combined Liver Cancer (HKCLC) classification. (2011) (0)
Title Survival Analysis of Re-resection Versus Radiofrequency Ablation for Intrahepatic Recurrence After Hepatectomy for Hepatocellular Carcinoma (2011) (0)
391 POSTER The significance of Pyk2 in hepatocellular carcinoma invasiveness (2006) (0)
Title Inflammatory pseudotumor of the liver in association with a gastrointestinal stromal tumor: A case report (2004) (0)
Title A garlic derivative , s-allylcysteine ( sac ) , suppresses proliferationand metastasis of hepatocellular carcinoma (2012) (0)
CONCURRENT SESSIONS: INVITED SPEAKERS (2010) (0)
Title Genome-wide association study of hepatocellular carcinoma in Southern Chinese patients with chronic hepatitis B virus infection (2011) (0)
Role of Serum Alpha-Fetoprotein Monitoring in Detection of Recurrent Hepatocellular Carcinoma after Curative Hepatectomy (2003) (0)
A multi-center phase II trial of bevacizumab (B) pre- and post-transarterial chemoembolization (TACE) treatment for patients with localized unresectable HCC: interim safety report (2010) (0)
Title A phase 1 dose-escalating study of pegylated recombinant human arginase 1 ( Peg-rhArg 1 ) in patients with advanced hepatocellular carcinoma (2012) (0)
Title Tuberculosis of pancreas and peripancreatic lymph nodes inimmunocompetent patients : Experience from China (2003) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Ronnie Tung‐ping Poon?

Ronnie Tung‐ping Poon is affiliated with the following schools:

Ronnie Tung‐ping Poon's Academic­Influence.com Rankings

Why Is Ronnie Tung‐ping Poon Influential?

Ronnie Tung‐ping Poon's Published Works

Published Works

What Schools Are Affiliated With Ronnie Tung‐ping Poon?

Ronnie Tung‐ping Poon's AcademicInfluence.com Rankings